Skip to main content
Premium Trial:

Request an Annual Quote

In Connecticut, Bigger Bucks for Biotech: R&D Up 18 Percent In 2001

NEW YORK, March 27-Biotech investment jumped about 18 percent last year in Connecticut, according to an analysis released yesterday evening by an industry group.


In 2001, biomedical R&D spending in Connecticut climbed to $3.6 billion, up from $3.1 billion in 2000.


Most of that investment came from pharmaceutical companies, which plowed nearly $3 billion into the sector in 2001. Biotech firms accounted for only about $277 million of the total research investment.


The sector added roughly 500 new jobs last year in the state, for a total Connecticut biomedical labor force of about 16,500.


The analysis, part of an annual economic report, was conducted by Connecticut United for Research Excellence, a state umbrella group for biomedical researchers in industry and academia.


Research firms in the survey included Boehringer Ingelheim, Bristol-Myers Squibb, Cellular Genomics, CuraGen Corporation, Genaissance Pharmaceuticals, and Protein Sciences Corporation. Academic institutes included the University of Connecticut and Yale University.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.